Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atomoxetine · 1 trial · 3 indications
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) measures the severity of cognitive impairment in dementia. Scores range from 0 to 70, with higher scores indicating worse cognitive performance (Unit of Measure: ADAS-Cog score (0-70). ADAS-Cog will be administered at baseline, month 6, month 12, and month 18 (end of study), and change over time will be assessed.
The Amsterdam Instrumental Activities of Daily Living Questionnaire - Short Version (A-IADL-Q-SV) assesses functional impairment in instrumental activities of daily living. Scores range from 0 to 100, with higher scores indicating better functional performance (Unit of Measure: A-IADL-Q-SV score (0-100). The A-IADL-Q-SV will be administered at baseline, month 6, month 12, and month 18 (end of study), and change over time will be evaluated.
| Arm | Type | Description |
|---|---|---|
| Standard of Care + Placebo | PLACEBO_COMPARATOR | Placebo arm (Oral capsule matching active treatments) |
| Standard of Care + Atomoxetine | ACTIVE_COMPARATOR | Atomoxetine (Oral, up to 100 mg/day) |
| Standard of Care + Metformin | ACTIVE_COMPARATOR | Metformin (immediate release) Oral, up to 2000 mg/day |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Oral capsule matching active treatments |
| Atomoxetine | DRUG | Atomoxetine (Oral, up to 100 mg/day) |
| Metformin 1000 mg Oral Tablet | DRUG | Metformin IR Oral, up to 2000 mg/day |
Inclusion Criteria * Patient meets all inclusion criteria: 1\. Adults aged ≥55 years on the day of screening, no upper age limit 2. Either: 1. Confirmed clinical diagnosis of Alzheimer's Disease (AD) 2. Confirmed clinical diagnosis of Mixed Dementia consisting of Alzheimer's Disease and Vasc...
Top 20 of 24 competitors
Atomoxetine is a small molecule being studied for the treatment of symptomatic Alzheimer's Disease, including mild cognitive impairment due to Alzheimer's Disease and Alzheimer Disease Dementia. It is currently in Phase 3 clinical development as an investigational therapy for these conditions.
Atomoxetine is a small molecule therapeutic being evaluated for its effects in Alzheimer's Disease. The specific molecular target of Atomoxetine in this context has not been disclosed in the available clinical trial information.
Atomoxetine is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting a Phase 3 clinical trial to evaluate the drug for Alzheimer's Disease.
Atomoxetine is in Phase 3 clinical development for Alzheimer's Disease. It is currently being evaluated in a randomized, double-blind, placebo-controlled trial with an enrollment of 1,200 participants, and the trial is actively recruiting patients.
Atomoxetine is being studied in a Phase 3 clinical trial with the identifier NCT07724132. This trial is titled 'An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease' and is recruiting participants in the United Kingdom.
Atomoxetine is a distinct investigational drug being developed by United Therapeutics Corporation for Alzheimer's Disease. It is not identified as being the same as any other marketed or investigational Alzheimer's treatment in the available clinical trial information.